Integrated safety and microbiota profiling of fulvic acid formulations across in vitro and in vivo models
Key Findings
- Two fossil-based FA formulations (MLG-50 and alkaline MLG-A50, ~23-34 million years old deposit) tested
- High cytocompatibility across broad concentration range in L929 fibroblasts, LoVo epithelial cells, HepG2 hepatocytes
- Genotoxicity levels significantly lower than reference dietary compounds; no relevant nuclear abnormalities
- MLG-A50 enhanced intestinal epithelial cell growth at sub-toxic concentrations
- MLG-A50 showed pro-regenerative effect in LoVo wound healing scratch assay — increased wound closure rate
- Anti-inflammatory: suppression of NF-κB activation in LPS-stimulated monocytes via LPS neutralization and receptor-level inhibition
- Reduced TNF and IL-6 secretion without impairment of IL-10 production
- In vitro and in vivo microbiome profiling: stimulated growth of Lactobacillus and Bifidobacterium
- Combined safety + bioactivity + microbiome assessment in single experimental framework
Comprehensive 2026 study evaluating safety and multifunctional bioactivity of fossil-derived fulvic acid formulations. Notable for being the first study to integrate cytocompatibility, genotoxicity, anti-inflammatory signaling, regenerative potential, and microbiome effects in a single experimental framework. Key safety finding: FA formulations showed high cytocompatibility and genotoxicity levels significantly lower than common dietary compounds. Anti-inflammatory mechanism identified: NF-κB suppression via both LPS neutralization and receptor-level inhibition, reducing TNF and IL-6 while preserving anti-inflammatory IL-10. Pro-regenerative effect confirmed in wound healing assay. Microbiome benefit: selective stimulation of beneficial bacteria (Lactobacillus, Bifidobacterium).